PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research

PS5-06-02: Cdk4/6 inhibitor-induced interstitial lung disease: a rare but severe complication in breast cancer treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

SHS. A. HaddadDPD. U. PortilloANA. M. Nambiar

Discussion

Loading...

Member takes

Overview

Case report reveals severe interstitial lung disease in a breast cancer patient treated with CDK4/6 inhibitors, suggesting a need for monitoring.

Key Points

  • Investigate the occurrence of interstitial lung disease (ILD) as a severe complication in patients treated with CDK4/6 inhibitors for breast cancer.
  • Case study of a 61-year-old female breast cancer patient with ILD after CDK4/6 inhibitor therapy.
  • Detailed examination included bronchoscopy, lung biopsy, and treatments with corticosteroids and infliximab.
  • Multidisciplinary management involved oncology and pulmonology teams.
  • Patient developed acute respiratory failure after six months of CDK4/6 inhibitor treatment.
  • Bronchoscopy indicated focal fibrosis and inflammation without infection or malignancy.
  • Referral for lung transplantation was considered due to chronic, irreversible lung disease.

Cite This Study

Haddad et al. (2026) studied this question.

synapsesocial.com/papers/6996a8e3ecb39a600b3f0069https://doi.org/10.1158/1557-3265.sabcs25-ps5-06-02
View Full Paper
Ask AI
Bookmark
Share